Bruera E., MacMillan K., Hanson J., MacDonald R.N.
Palliative care in a cancer
center: results in 1984 versus 1987 // J. Pain. Symptom. Manage. — 1990. — V. 5(1). —
P. 1 5.
Brule G.
Co operative clinical study of 178 patients treated with "Nolvadex". The
hormonal control of breast cancer // Cheshire. — 1978. — P. 35 39.
Buckwalter J.A., Brandser E.A.
Metastatic disease of the skeleton // Am. Fam.
Physician 1997. — V. 55(5). — P. 1761 1768.
Buffaz P.D., Gauchez A.S., Caravel J.P., Vuillez J.P., Cura C., Agnius+Delord C.,
Fagret D.
Can tumour marker assays be a guide in the prescription of bone scan for breast
and lung cancers? // Eur. J. Nucl. Med. — 1999. — V. 26(1). — P. 8 11.
Bull J.M., Tormey D.C., Li S.H., Carbone P.P., Falkson G., Blim J., Perlin E, Simon
R.
Randomized comparative trial of adriamycin versus methotrexate in combination drug
therapy // Cancer. — 1978. — V. 4. — P.1649 1657.
Bundred N.J., Walls J., Ratcliffe W.A.
Parathyroid hormone related protein, bone
metastases and hypercalcaemia of malignancy // Ann. R. Coll. Surg. Engl. — 1996 V.
78(4). — P. 354 3588.
Burstein H.J., Younger J., Bunnell C.A.,
è ñîàâò. Weekly docetaxel (Taxotere) for
metastatic breast cancer: a phase II trial // Proc. Annu Meet. Am. Soc. Clin. Oncol. —
1999. — V. 18 — P. 127a (Abstract 485).
Burtis W.J., Brady T.G., Wu T.L., Ersbak J., Stewart A.F.
Rapid immunoradiomet
ric assay (IRMA) for parathyroid hormone like protein (PTHLP) // J. Bone Miner. Res. —
1989. — V.4 (Suppl.). — P. 310.
Butzelaar R.M.J.M., Van Dongen J.A., De Graaf P.W.
è ñîàâò. Bone scintigraphy in
patients with operable breast cancer stages I and II. Final conclusion after five year follow
up // Eur. J. Cancer and Clin. Oncol. — 1984. — V 20. —¹ 7. — P. 877 880.
Buzdar A.U., Holmes E.A., Hortobagyi G.N.
Paclitaxel in the treatment of metastatic
breast cancer // M.D.Anderson Cancer Center experience. Semin. Oncol. — 1995. —
V. 22. — P. 101 104.
Buzdar A.U., Plourde P.V., Hortobagyi G.N.
Aromatase inhibitors in metastatic
breast cancer // Semin. Oncol. — 1996. — V. 23. — P. 28 32.
Buzdar A.U., Jones S.E., Vogel C.L.,
è ñîàâò. A phase III trial comparing anastro
zole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol
acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study
Group // Cancer
.
–1997 V. 79. — P. 730 739.
Buzdar A., Jonat W., Howell A.,
è ñîàâò. Anastrozole versus megestrol acetate in the
treatment of postmenopausal women with advanced breast carcinoma: results of a survival
update based on a combined analysis of data from two mature Phase III trials. Arimidex
Study Group // Cancer. — 1998. — V.83. — P. 1142 1152.
Calle R., Londora R., Vileog J.R.
è ñîàâò. Cancers du sein. Diagnostic des metastases
intra cliniques ossenses. Valeur previsionnelle de la scintigraphie // Bull. Cancer. — 1980. —
V. 67. — P. 313 317.
Campbell C., Blamey R.W., Elston C.W., Nicholson R., Griffiths K., Haybittle J.L.
Oestrogen receptor status and sites of metastases in breast cancer // Brit. J. Cancer. —
1981. — V. 44. — P.456 459.
Campbell F.C., Blamey R.W., Woolfson A.M.J., Elston C.W., Hosking D.J.
Calcium
excretion (CaE) in metastatic breast cancer // Br. J. Surg. — 1983. — V. 70. — P. 202 204.
Campora E., Merlini L., Pace M.,
è ñîàâò. The incidence of narcotic –induced eme
sis // J. Pain. Symptom. Manag. — 1991. — V.6(7). — P. 428 430.
219
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
